# Corsair Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corsair-pharma

- Industry: Pharmaceuticals
- Headquarters: Sunnyvale, US
- Website: www.corsairpharma.com/
- Total disclosed funding: $23M
- Latest round: Series B (Sep 20, 2023)
- Investors on record: 5

## About

Based in California, US, and founded in 2011, Corsair Pharma, Inc. operates as a manufacturing company that manufactures transdermal patches that help patients with pulmonary arterial hypertension (HAP). In September 2023, Corsair Pharma, Inc. raised USD 23 million in Series B funding led by investor New Rhein Healthcare Investors, with the participation of Junson Capital, Midas Capital, Plaisance Capital, and Primavera Capital. As of August 2020, the company’s CEO is Bobby Singh.

Corsair Pharma, Inc.’s flagship product candidate is a prodrug of treprostinil, a medication used to treat pulmonary arterial hypertension (PAH). The company provides the prodrug treprostinil via a proprietary patch, providing consistent and convenient therapy without the need for invasive procedures like catheter insertion or subcutaneous pumps to enhance patient comfort and reduce the side effects associated with traditional treatment methods.
 
The company plans to use the September 2023 funding to advance its clinical product offerings.

## Funding rounds

- Series B, Sep 20, 2023, $23M — Plaisance Capital, Primavera Capital Group, New Rhein Healthcare Investors, Junson Capital, Midas Capital

## Investors

- Plaisance Capital — Series B
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series B
- New Rhein Healthcare Investors (https://capitalatlas.ai/funds/new-rhein-healthcare-investors) — Series B
- Junson Capital — Series B
- Midas Capital — Series B